Clinical trials: RAS Wild Type
Metastatic Colorectal Cancer
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
This is a non-profit phase II, randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy, compared to cetuximab alone, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients…
- Trial name
- NCT05291156
- Testing
- Cetuximab, Avelumab
- Where
- 24 sites in Italy
- Volunteers
- 173 people
- Sponsor
- University of Campania Luigi Vanvitelli
Colorectal Cancer Metastatic
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
The goal of this clinical trial is to learn if the application of the chemotherapy FOLFIRI and cetuximab works better when given with scheduled breaks or continuously in adults with metastatic colorectal cancer.
- Trial name
- FIRE-11 (NCT07004413)
- Testing
- FOLFIRI+cetuximab, Guardant360 ctDNA assay
- Where
- Germany
- Volunteers
- 267 people
- Sponsor
- Charite University, Berlin, Germany
Colon Cancer, Rectal Cancer
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT01126450
- Testing
- lenalidomide, cetuximab, mutation analysis
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
This phase II trial studies how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is negative…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8
- Trial name
- NCT03992456
- Testing
- Panitumumab, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 18 sites in United States
- Volunteers
- 12 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Neoplasms
A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer
This is a single arm, open-label, multi-center clinical trial to evaluate the efficacy and safety of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil-based chemotherapy plus cetuximab for…
- Trial name
- NCT02717923
- Testing
- maintenance treatment with capecitabine plus cetuximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Huazhong University of Science and Technology
Metastatic Colorectal Cancer
Pharmacokinetics and Metabolic Activation of Capecitabine
The objective of this pharmacokinetic study is to exclude a possible influence of CETUX on the plasma disposition and metabolic activation of Capecitabine (CCB) and when this regimen is given combined with Oxaliplatin (OxPt).
- Trial name
- NCT01579357
- Testing
- blood samples
- Where
- 3 sites in Austria
- Volunteers
- 24 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Colorectal Cancer, Liver Metastases
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in…
- Trial name
- NCT06280495
- Testing
- Oxaliplatin, Fluorouracil, Serplulimab
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Liver Metastases
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Evidence suggests that the addition of cetuximab or bevacizumab to doublet regimens could improve response rate and resectability rate of liver metastases and survival in colorectal liver metastases (CRLM).
- Trial name
- NCT04687631
- Testing
- mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Fudan University
Colorectal Cancer
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00640081
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 25 sites in Cyprus, United Kingdom
- Volunteers
- 169 people
- Sponsor
- Cheryl Pugh
Peritoneal Carcinomatosis, Colorectal Cancer Metastatic
Combined Anticancer Treatment of Advanced Colon Cancer
The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and bidirectional hyperthermic intraperitoneal…
- Trial name
- COMBATAC (NCT01540344)
- Testing
- CRS, HIPEC
- Where
- 7 sites in Germany
- Volunteers
- 26 people
- Sponsor
- University of Regensburg
Metastatic Colorectal Cancer
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment…
- Trial name
- NCT05694936
- Testing
- Sodium Valproate, Panitumumab, Cetuximab
- Where
- 12 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Solid Tumors (Phase 1), HNSCC
MTX-531-001 Phase 1 Study in Advanced Solid Tumors
This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors.
- Conditions
- Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer
- Trial name
- NCT07874880
- Testing
- MTX-531
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- MEKanistic Therapeutics, Inc.
Stage II Colon Cancer, Stage III Colon Cancer
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
The aims of this study are to evaluate if an intensified adjuvant treatment with FOLFOXIRI could increase the rate of cases with undetectable ct-DNA after chemotherapy and to evaluate if a further adjuvant treatment with…
- Conditions
- Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
- Trial name
- ERASE-CRC (NCT05062889)
- Testing
- 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule
- Where
- 28 sites in Italy
- Volunteers
- 477 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
The purpose of this study is to observe and evaluate the efficacy and safety of adebrelimab plus cetuximab and chemotherapy for patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer.
- Trial name
- NCT06231017
- Testing
- Adebrelimab + Cetuximab+ Chemotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Colorectal Cancer
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT02785068
- Testing
- MM-151, nal-IRI, Leucovorin
- Sponsor
- Merrimack Pharmaceuticals
Colo-rectal Cancer
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B).
- Trial name
- NCT05074966
- Testing
- Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer Metastatic
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
To estimate progression-free-survival at 6 months in subjects treated in first-line with panitumumab and FOLFOX and with wild type RAS mCRC (metastatic colorectal cancer) confirmed in liquid biopsies before starting second line…
- Trial name
- BEYOND (NCT03751176)
- Testing
- Panitumumab, Irinotecan, Folinic acid
- Where
- 18 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Rectal Cancer
Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)
The objective of this trial is to obtain evidence that, in patients with RAS wildtype tumors, a chemotherapy-free combined modality treatment with panitumumab is clearly superior to radiotherapy alone and achieves a pCR rate…
- Trial name
- NEO-RIT (NCT01257360)
- Testing
- Panitumumab, Radiation of the pelvis
- Where
- 5 sites in Germany
- Volunteers
- 59 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Colorectal Cancer Stage IV
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients.
- Trial name
- IMPROVE (NCT04425239)
- Testing
- Panitumumab
- Where
- Italy
- Volunteers
- 151 people
- Sponsor
- National Cancer Institute, Naples
Advanced Colorectal Cancer
Study of Nimotuzumab to Treat Colorectal Cancer
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT00972465
- Testing
- Nimotuzumab and chemotherapy
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Peking University